
Hypofractionated spot-scanning proton therapy offers promising local control with acceptable toxicity in patients with head and neck malignant mucosal melanoma. In a 39-patient retrospective study, 3-year local control reached 83%, though progression-free survival remained limited due to distant metastases. Quality of life was largely maintained, with expected declines in pain, swallowing, and oral function. Larger tumors predicted poorer outcomes.
Like
Save
Share